文献速递认知障碍与痴呆

甘特珠单抗长期治疗显性遗传阿尔茨海默病的开放标签扩展研究

Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial.
PubMed 文献 · Lancet Neurol · 2025-01-01

DIAN-TU平台试验的开放标签扩展研究评估高剂量甘特珠单抗长期治疗显性遗传阿尔茨海默病的安全性和疗效。

要点

  • 长期完全清除淀粉样斑块可能延迟症状发作和痴呆进展
  • 部分或短期淀粉样蛋白清除未显示显著临床效果
  • 淀粉样蛋白相关影像异常发生率为53%(39/73)

核心结论

  • 部分或短期淀粉样蛋白清除未显示显著临床效果,但长期完全清除可能延迟症状发作和痴呆进展。
  • 结论受OLE设计和外部对照限制,需长期试验确认。

研究设计与样本

  • DIAN-TU-001为随机、安慰剂对照、双盲、2/3期多臂试验,评估solanezumab或gantenerumab对比安慰剂。
  • OLE研究在8个国家18个中心进行,纳入74人,73人接受gantenerumab治疗,皮下剂量递增至每2周1500 mg。
  • 因缺乏监管路径,研究在预设中期分析后提前终止,最终分析主要终点为3年时PiB-PET SUVR,mITT组55人。

主要发现

  • 淀粉样蛋白相关影像异常发生率为53%(39/73),其中微出血47%(34/73)、水肿30%(22/73)、浅表铁质沉着相关6%(5/73)。
  • 未发生治疗相关的大出血或死亡。

关键数值与推荐

  • 皮下gantenerumab剂量递增至每2周1500 mg。
  • OLE纳入标准:DIAN-TU-001双盲期参与者,已知突变状态,CDR全局评分0至1。

临床怎么用

  • 长期高剂量gantenerumab治疗与淀粉样斑块显著清除相关。
  • 治疗中淀粉样蛋白相关影像异常发生率较高,需监测微出血和水肿。

局限性

  • OLE设计和使用外部对照限制了结论。
  • 结论需长期试验确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Amyloid plaque removal by monoclonal antibody therapies slows clinical progression in symptomatic Alzheimer's disease; however, the potential for delaying the onset of clinical symptoms in asymptomatic people is unknown. The Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) is an ongoing platform trial assessing the safety and efficacy of multiple investigational products in participants with dominantly inherited Alzheimer's disease (DIAD). Based on findings of amyloid removal and downstream biological effects from the gantenerumab group of the platform trial, we continued a 3-year open-label extension (OLE) study to assess the safety and efficacy of long-term treatment with high doses of gantenerumab. METHODS: The randomised, placebo-controlled, double-blind, phase 2/3 multi-arm trial (DIAN-TU-001) assessed solanezumab or gantenerumab versus placebo in participants who were between 15 years before and 10 years after their estimated years to symptom onset and who had a Clinical Dementia Rating (CDR) global score of 0 (cognitively normal) to 1 (mild dementia). This study was followed by an OLE study of gantenerumab treatment, conducted at 18 study sites in Australia, Canada, France, Ireland, Puerto Rico, Spain, the UK, and the USA. For inclusion in the OLE, participants at risk for DIAD had participated in the double-blind period of DIAN-TU-001 and were required to know their mutation status. We investigated increasing doses of subcutaneous gantenerumab up to 1500 mg every 2 weeks. Due to the lack of a regulatory path for gantenerumab, the study was stopped early after a prespecified interim analysis (when most participants had completed 2 years of treatment) of the clinical measure CDR-Sum of Boxes (CDR-SB). The primary outcome for the final analysis was the amyloid plaque measure 11C-Pittsburgh compound-B positron emission tomography (PiB-PET) standardised uptake value ratio (SUVR [PiB-PET SUVR]) at 3 years, assessed in the modified intention-to-treat group (mITT; defined as participants who received any gantenerumab treatment post-OLE baseline, had at least one PiB-PET SUVR assessment before gantenerumab treatment, and a post-baseline assessment). All participants who received at least one dose of study drug in the OLE were included in the safety analysis. DIAN-TU-001 (NCT01760005) and the OLE (NCT06424236) are registered with ClinicalTrials.gov. FINDINGS: Of 74 participants who were recruited into the OLE study between June 3, 2020, and April 22, 2021, 73 were enrolled and received gantenerumab treatment. 47 (64%) stopped dosing due to early termination of the study by the sponsor, and 13 (18%) prematurely discontinued the study for other reasons; 13 people completed 3 years of treatment. The mITT group for the primary analysis comprised 55 participants. At the interim analysis, the hazard ratio for clinical decline of CDR-SB in asymptomatic mutation carriers was 0·79 (n=53 [95% CI 0·47 to 1·32]) for participants who were treated with gantenerumab in either the double-blind or OLE period (Any Gant), and 0·53 (n=22 [0·27 to 1·03]) for participants who were treated with gantenerumab the longest (Longest Gant). At the final analysis, the adjusted mean change from OLE baseline to year 3 in PiB-PET SUVR was -0·71 SUVR (95% CI -0·88 to -0·53, p<0·0001). Amyloid-related imaging abnormalities occurred in 53% (39 of 73) of participants: 47% (34 of 73) with microhaemorrhages, 30% (22 of 73) with oedema, and 6% (five of 73) were associated with superficial siderosis. No treatment-associated macrohaemorrhages or deaths occurred. INTERPRETATION: Partial or short-term amyloid removal did not show significant clinical effects. However, long-term full amyloid removal potentially delayed symptom onset and dementia progression. Our conclusions are limited due to the OLE design and use of external controls and need to be confirmed in long-term trials. FUNDING: National Institute on Aging, Alzheimer's Association, GHR Foundation, and F Hoffmann-La Roche/Genentech.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Bateman RJ, Li Y, McDade EM, et al. Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial. Lancet Neurol. 2025. PMID: 40120616. doi:10.1016/S1474-4422(25)00024-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。